A team of researchers from the Universitat Autònoma de Barcelona, lead by Professor Jordi Alberola, has demonstrated the efficacy and safety of a new type of antibiotic, belonging to the family called antimicrobial peptides, for treating canine leishmaniasis, which is a disease that also affects humans. It is the first time that these antibiotics have been demonstrated to be useful against parasitic diseases in real clinical situations. The antibiotic can also improve treatment of other infections, parasitic or not, in that no side effects have been observed and it is very difficult for organisms to develop resistance to them. In addition, it can also have a direct application as a drug for treating co-infection of leishmaniasis with HIV, which 10 % of people with AIDS suffer from. The findings will be published this month (February) in the magazine Antimicrobial Agents and Chemotherapy, which is the most prestigious in its field.
Twelve million people around the world are affected by leishmaniasis; 400 million more are at risk of suffering the disease and every year between 60,000 and 100,000 people die from it. Furthermore, nearly 2 million new cases are reported every year. The different forms of leishmaniasis are caused by unicellular parasites of the Leishmania genus, which are mainly spread by biting insects, similar to mosquitoes, called phlebotoms. Clinical manifestations range from slight cutaneous lesions to visceral complications that may lead to the individual’s death.
Dogs are the main reservoir of the parasite in Spain and in the rest of the Mediterranean basin, the Middle East and South America. Epidemiological studies show that around 70% of dogs in the Mediterranean area are infected. Consequently, eradication of the disease in dogs is considered to be one of the main objectives for improving human health.
Octavi López Coronado | alfa
Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn
Foods of the future
15.08.2018 | Georg-August-Universität Göttingen
There are currently great hopes for solid-state batteries. They contain no liquid parts that could leak or catch fire. For this reason, they do not require cooling and are considered to be much safer, more reliable, and longer lasting than traditional lithium-ion batteries. Jülich scientists have now introduced a new concept that allows currents up to ten times greater during charging and discharging than previously described in the literature. The improvement was achieved by a “clever” choice of materials with a focus on consistently good compatibility. All components were made from phosphate compounds, which are well matched both chemically and mechanically.
The low current is considered one of the biggest hurdles in the development of solid-state batteries. It is the reason why the batteries take a relatively long...
New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference
Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...
Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
17.08.2018 | Event News
08.08.2018 | Event News
27.07.2018 | Event News
20.08.2018 | Information Technology
20.08.2018 | Life Sciences
20.08.2018 | Information Technology